이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Biomarker Panel Development for Early Identification of Worsening Heart Failure and Improved Post-acute Care

2026년 9월 25일 업데이트: CHAO-HUNG WANG, MD, Chang Gung Memorial Hospital

Integration of Metabolic Assessment on Phenylalanine Axis and Clinical Databank-based Artificial Intelligence Computation in Heart Failure: Biomarker Panel Development for Early Identification of Worsening Heart Failure and Improved Post-acute Care

Heart failure is a complex clinical syndrome with high hospitalization rates and high mortality risks. While N-terminal-pro B-type natriuretic peptide (NT-proBNP) is widely used in clinical practice to assist in diagnosis and assessment, its ability to detect prognosis in heart failure remains insufficient. Recent scientific research has found that phenylalanine in the blood and its endogenous toxic substance phenylpyruvate are closely related to impaired energy synthesis in heart muscle cells, making them highly promising next-generation long-term biomarkers. Our research team has previously developed a "risk score" prediction model that combines phenylpyruvate levels in the blood with clinical data; this project aims to further confirm its clinical value.

Therefore, the investigators cordially invite heart failure patients who are being followed up in the cardiology outpatient clinic to have their "phenylalanine" and "phenylpyruvic acid" concentrations measured in a small amount of blood. This data, combined with clinical data, will be used to calculate a "Risk Score" to identify high-risk heart failure patients earlier.

연구 개요

상태

아직 모집하지 않음

상세 설명

I. Background:

Heart failure is a complex syndrome. Any abnormality in cardiac structure or function that affects ventricular congestion or ejection can lead to heart failure. Clinically, heart failure is classified into four categories based on the presence or absence of abnormal left ventricular ejection fraction (LVEF): heart failure with reduced ejection fraction (HFrEF), heart failure with mildly reduced ejection fraction (HFmrEF), heart failure with normal left ventricular ejection fraction (LVEF ≥ 50%), and heart failure with improved ejection fraction (HFimpEF) (previously LVEF ≤ 40%, followed by follow-up to LVEF > 40%). The New York Heart Association functional classification (NYHA Fc) further classifies participants into grades I through IV based on the degree of limitation in physical activity. Participants diagnosed with HFrEF who exhibit symptoms of NYHA Fc grades 2 to 4 require guideline-directed medical therapy (GDMT). However, a good assessment strategy for long-term follow-up after treatment remains lacking.

Among existing diagnostic and treatment strategies, NT-proBNP is the most widely used biomarker for diagnosis and prognostic assessment. However, its ability to identify early abnormalities of heart failure relapse, quantify metabolic abnormalities caused by heart failure, and detect endogenous toxicities caused by heart failure is still insufficient, and its assessment of heart failure prognosis is also imprecise. Elevated blood concentrations of phenylalanine and its metabolite phenylpyruvate are currently considered highly relevant to the pathophysiological mechanisms of heart failure exacerbation and can lead to the accumulation of phenylalanine and its downstream metabolite phenylpyruvate in the body fluids and tissues of heart failure patients, further worsening cardiac function. Furthermore, these metabolic disorders are closely associated with oxidative stress, mitochondrial dysfunction, and impaired energy synthesis. These alterations have been confirmed in animal models and clinical patients. They hold great potential as biomarkers for long-term monitoring by capturing early metabolic abnormalities and endogenous toxicities in heart failure.

Therefore, this study focuses on phenylalanine and phenylpyruvate metabolites to assess their correlation with patient prognosis. In another part, the investigators used the Chang Gung database for data analysis and integrated metabolite testing and clinical data into a "Risk Score" to identify high-risk patients. This aims to provide heart failure patients with more precise metabolic assessment and clinical management tools, thereby improving their quality of life and reducing disease-related mortality and hospitalization rates.

II. Objectives:

  1. To uniformly quantify phenylalanine and phenylpyruvate using high-order mass spectrometry and verify their correlation with the worsening of heart failure.
  2. To use the developed "Risk Score" in prospective, multicenter, observational validation studies (including Chang Gung Memorial Hospital, Mackay Memorial Hospital, Cheng Hsin General Hospital, and National Taiwan University Hospital) to assess its clinical predictive ability, calibration, discrimination, and cross-center generalization ability in participants with chronic outpatient heart failure.

III. Methods The investigators will enroll participants at outpatient clinic at different hospitals. Then, fasting blood (3 ml) will be collected once to get the plasma after centrifugation. Phenylpyruvate (PPA) concentration will be measured by liquid chromatography-mass spectrometry (LC-MS/MS).

Based on clinical information and the blood levels of NT-proBNP and PPA, a risk score will be calculated.

For clinical outcomes, the investigators will follow up participants' events of recurrent worsening heart failure, which will be explained in the primary and secondary outcome section.

The investigators will do statistical analysis to see the prognostic value of PPA concentrations and the risk scores.

연구 유형

관찰

등록 (추정된)

800

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Outpatients with chronic heart failure

설명

Inclusion Criteria:

  • Adult men and women aged 18 to 85 years
  • Patients with chronic heart failure diagnosed as stage C or D in outpatient settings. Stage definitions are based on the American Heart Association Heart Failure Classification System.
  • Patients with a recorded left ventricular ejection fraction (LVEF) ≤ 40% in their medical history, but LVEF is not restricted at the time of admission to include patients with heart failure with reduced ejection fraction (HFrEF), heart failure with improved ejection fraction (HFimpEF), and those potentially progressing to heart failure with mildly reduced ejection fraction (HFmrEF)/ heart failure with preserved ejection fraction (HFpEF).
  • Patients who have recently been hospitalized for acute heart failure must be discharged and have been clinically stable for at least three months before inclusion.

Exclusion Criteria:

  • Patients with other serious comorbidities that significantly impact life expectancy or survival within three months based on clinical assessment, such as terminal cancer or severe multiple organ failure.
  • Patients with New York Heart Association (NYHA) class IV and unstable clinical condition requiring frequent intravenous therapy or hospitalization.
  • Patients currently receiving maintenance hemodialysis or peritoneal dialysis.
  • Patients who are unable to complete basic follow-up, lack key clinical data, or do not consent to the use of the specimen and data.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: COHORT
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
outpatients with chronic heart failure

Inclusion Criteria:

  • Adult men and women aged 18 to 85 years
  • Patients with chronic heart failure diagnosed as stage C or D in outpatient settings. Stage definitions are based on the American Heart Association Heart Failure Classification System.
  • Patients with a recorded left ventricular ejection fraction (LVEF) ≤ 40% in their medical history, but LVEF is not restricted at the time of admission to include patients with heart failure with reduced ejection fraction (HFrEF), heart failure with improved ejection fraction (HFimpEF), and those potentially progressing to heart failure with mildly reduced ejection fraction (HFmrEF)/ heart failure with preserved ejection fraction (HFpEF).
  • Patients who have recently been hospitalized for acute heart failure must be discharged and have been clinically stable for at least three months before inclusion.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Recurrent worsening heart failure (HF) event burden
기간: within 36 months after enrollment

Recurrent worsening heart failure (HF) event burden within 36 months after enrollment. Events include:

  1. Hospitalization for worsening HF
  2. HF worsening treated at emergency or outpatient clinic
  3. intensive diuretic care event
  4. All-cause death
within 36 months after enrollment

2차 결과 측정

결과 측정
측정값 설명
기간
Composite events
기간: within 36 months after enrollment
  1. First hospitalization for worsening heart failure, emergency heart failure care, or all-cause death within 36 months
  2. Number of heart failure hospitalizations, number of emergency/unexpected care visits, and total days of hospitalization within 36 months
within 36 months after enrollment

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 9월 18일

기본 완료 (추정된)

2030년 10월 31일

연구 완료 (추정된)

2030년 10월 31일

연구 등록 날짜

최초 제출

2026년 9월 18일

QC 기준을 충족하는 최초 제출

2026년 9월 18일

처음 게시됨 (실제)

2026년 9월 24일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 29일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 25일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 202500252B0C6002

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다